Galera Therapeutics (GRTX) announced the appointment of accomplished pharmaceutical sales, market access, and commercial operations executives to Galera’s senior commercial leadership team, effective immediately. Under the direction of Mark Bachleda, Pharm.D., MBA, Galera’s Chief Commercial Officer, the team will be responsible for building out the Company’s commercial operations, strategy development, and execution in preparation for the potential U.S. commercial launch of avasopasem in 2023. The Company’s appointments include: Patrick Campbell as Vice President of Sales & Account Management; Elizabeth Turner as Vice President of Market Access; Henning Thorsen as Vice President of Commercial Operations. The new senior leaders join Lorraine Walker, Pharm.D., Galera’s Vice President of Marketing. Turner joins Galera from Anton Health. Campbell joins Galera from Amgen (AMGN) where he recently served as Executive National Sales Director for Amgen’s oncology solid tumor portfolio. Thorsen joins Galera from Better Therapeutics (BTTX) where he served as Head of Commercial Operations.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRTX:
- Galera Expands Commercial Leadership Team
- Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Biotech Alert: Searches spiking for these stocks today
- Galera Therapeutics price target lowered to $6 from $10 at H.C. Wainwright
- Galera Therapeutics price target lowered to $12 from $18 at Citi